In the past week, PHIO stock has gone up by 19.19%, with a monthly gain of 17.82% and a quarterly surge of 15.17%. The volatility ratio for the week is 11.44%, and the volatility levels for the last 30 days are 15.49% for Phio Pharmaceuticals Corp The simple moving average for the past 20 days is -3.44% for PHIO’s stock, with a -14.86% simple moving average for the past 200 days.
Is It Worth Investing in Phio Pharmaceuticals Corp (NASDAQ: PHIO) Right Now?
The 36-month beta value for PHIO is also noteworthy at 0.81. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PHIO is 4.75M, and at present, short sellers hold a 5.78% of that float. The average trading volume of PHIO on May 13, 2025 was 3.17M shares.
PHIO) stock’s latest price update
Phio Pharmaceuticals Corp (NASDAQ: PHIO) has seen a rise in its stock price by 13.26 in relation to its previous close of 1.81. However, the company has experienced a 19.19% gain in its stock price over the last five trading sessions. newsfilecorp.com reported 2025-05-07 that Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual Meeting on May 10th Marlborough, Massachusetts–(Newsfile Corp. – May 7, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a complete pathologic response (100% tumor clearance) has been reported for 2 of 3 patients with cutaneous squamous cell carcinoma (cSCC) treated in the third dose cohort.
Analysts’ Opinion of PHIO
Many brokerage firms have already submitted their reports for PHIO stocks, with H.C. Wainwright repeating the rating for PHIO by listing it as a “Buy.” The predicted price for PHIO in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on August 05, 2020 of the previous year 2020.
PHIO Trading at 23.87% from the 50-Day Moving Average
After a stumble in the market that brought PHIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.06% of loss for the given period.
Volatility was left at 15.49%, however, over the last 30 days, the volatility rate increased by 11.44%, as shares sank -7.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +53.79% upper at present.
During the last 5 trading sessions, PHIO rose by +18.02%, which changed the moving average for the period of 200-days by -47.23% in comparison to the 20-day moving average, which settled at $2.1220. In addition, Phio Pharmaceuticals Corp saw 13.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHIO starting from Bitterman Robert J, who purchase 1,000 shares at the price of $0.74 back on Jun 07 ’24. After this action, Bitterman Robert J now owns 20,990 shares of Phio Pharmaceuticals Corp, valued at $740 using the latest closing price.
Bitterman Robert J, the President & CEO of Phio Pharmaceuticals Corp, purchase 1,000 shares at $0.75 during a trade that took place back on Jun 06 ’24, which means that Bitterman Robert J is holding 19,990 shares at $750 based on the most recent closing price.
Stock Fundamentals for PHIO
The total capital return value is set at -1.56. Equity return is now at value -114.83, with -94.69 for asset returns.
Currently, EBITDA for the company is -7.12 million with net debt to EBITDA at 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.65.
Conclusion
In summary, Phio Pharmaceuticals Corp (PHIO) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
